VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

COSTEM 2022 | The role of CAR-T therapy in high-risk LBCL in the first and second-line settings

Alberto Mussetti, MD, Institut Catala d’Oncologia Hospitalet, Barcelona, Spain, describes the merits and challenges of using anti-CD19 CAR-T therapy as a first- and second-line therapy to treat patients with high-risk large B-cell lymphoma (LBCL). This interview took place at the 7th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter